Aileron Therapeutics Stock Analysis
ALRN Stock | USD 4.75 0.01 0.21% |
Aileron Therapeutics is undervalued with Real Value of 13.45 and Target Price of 40.0. The main objective of Aileron Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Aileron Therapeutics is worth, separate from its market price. There are two main types of Aileron Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Aileron Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Aileron Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Aileron Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Aileron Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Aileron Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Aileron Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Aileron |
Aileron Stock Analysis Notes
About 18.0% of the company shares are held by institutions such as insurance companies. The book value of Aileron Therapeutics was presently reported as 1.41. The company recorded a loss per share of 3.42. Aileron Therapeutics had not issued any dividends in recent years. The entity had 1:20 split on the 11th of November 2022. Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts. Aileron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. For more info on Aileron Therapeutics please contact Joseph Yanchik at 617 995 0900 or go to https://www.aileronrx.com.Aileron Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aileron Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aileron Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aileron Therapeutics had very high historical volatility over the last 90 days | |
Aileron Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (15.73 M) with loss before overhead, payroll, taxes, and interest of (17.01 M). | |
Aileron Therapeutics currently holds about 32.38 M in cash with (19.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36. | |
Aileron Therapeutics has a frail financial position based on the latest SEC disclosures | |
Latest headline from news.google.com: LADENBURG THALMSH SH Boosts Aileron Therapeutics Price Target to 19.00 - Defense World |
Aileron Therapeutics Upcoming and Recent Events
Earnings reports are used by Aileron Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aileron Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
18th of March 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
18th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Aileron Largest EPS Surprises
Earnings surprises can significantly impact Aileron Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-08-11 | 2023-06-30 | -0.52 | -0.39 | 0.13 | 25 | ||
2023-05-08 | 2023-03-31 | -0.86 | -1.05 | -0.19 | 22 | ||
2022-11-01 | 2022-09-30 | -1.65 | -1.4 | 0.25 | 15 |
Aileron Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aileron Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aileron Therapeutics backward and forwards among themselves. Aileron Therapeutics' institutional investor refers to the entity that pools money to purchase Aileron Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Jfs Wealth Advisors, Llc | 2023-12-31 | 1.6 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.2 K | U.s. Bancorp | 2023-12-31 | 1.2 K | Blackrock Inc | 2023-12-31 | 189 | Bank Of America Corp | 2023-12-31 | 125 | Ica Group Wealth Management, Llc | 2023-12-31 | 100.0 | Fmr Inc | 2023-12-31 | 50.0 | Wells Fargo & Co | 2023-12-31 | 27.0 | Acadian Asset Management Llc | 2023-12-31 | 17.0 | Satter Management Co., L.p. | 2023-12-31 | 830.5 K | Geode Capital Management, Llc | 2023-12-31 | 57.3 K |
Aileron Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 80.62 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aileron Therapeutics's market, we take the total number of its shares issued and multiply it by Aileron Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Aileron Profitablity
Aileron Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Aileron Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Aileron Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Aileron Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Aileron Therapeutics' profitability requires more research than a typical breakdown of Aileron Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.47) | (0.49) | |
Return On Capital Employed | (0.13) | (0.14) | |
Return On Assets | (0.13) | (0.14) | |
Return On Equity | (2.28) | (2.40) |
Management Efficiency
Aileron Therapeutics has return on total asset (ROA) of (0.1499) % which means that it has lost $0.1499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2691) %, meaning that it created substantial loss on money invested by shareholders. Aileron Therapeutics' management efficiency ratios could be used to measure how well Aileron Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.49. In addition to that, Return On Capital Employed is likely to drop to -0.14. At this time, Aileron Therapeutics' Intangible Assets are very stable compared to the past year. As of the 24th of April 2024, Intangibles To Total Assets is likely to grow to 0.68, while Other Assets are likely to drop about 20.5 K.Last Reported | Projected for Next Year | ||
Book Value Per Share | 1.50 | 1.57 | |
Net Current Asset Value | 0.00 | 0.00 | |
Tangible Asset Value | 0.00 | 0.00 | |
Tangible Book Value Per Share | (17.10) | (17.96) | |
Enterprise Value Over EBITDA | (5.79) | (5.50) | |
Price Book Value Ratio | 2.04 | 2.14 | |
Enterprise Value Multiple | (5.79) | (5.50) | |
Price Fair Value | 2.04 | 2.14 | |
Enterprise Value | 88.1 M | 92.6 M |
The analysis of Aileron Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Aileron Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Aileron Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 2.243 |
Technical Drivers
As of the 24th of April, Aileron Therapeutics shows the Mean Deviation of 5.39, risk adjusted performance of 0.0471, and Downside Deviation of 7.85. Aileron Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Aileron Therapeutics, which can be compared to its peers. Please confirm Aileron Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Aileron Therapeutics is priced correctly, providing market reflects its regular price of 4.75 per share. Given that Aileron Therapeutics has jensen alpha of 0.4782, we suggest you to validate Aileron Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.Aileron Therapeutics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Aileron Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Aileron Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Aileron Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aileron Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aileron Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aileron Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Garner Charles over three weeks ago Disposition of 25597 shares by Garner Charles of Aileron Therapeutics at 2.34 subject to Rule 16b-3 | ||
James Windsor over a month ago Disposition of tradable shares by James Windsor of Aileron Therapeutics subject to Rule 16b-3 | ||
Armen Shanafelt over two months ago Acquisition by Armen Shanafelt of 20000 shares of Aileron Therapeutics subject to Rule 16b-3 | ||
Windsor James Brian over three months ago Purchase by Windsor James Brian of 225 shares of Aileron Therapeutics | ||
Windsor James Brian over three months ago Purchase by Windsor James Brian of 5076 shares of Aileron Therapeutics | ||
Windsor James Brian over three months ago Aileron Therapeutics exotic insider transaction detected | ||
Caleb Winder over six months ago Acquisition by Caleb Winder of 10000 shares of Aileron Therapeutics subject to Rule 16b-3 |
Aileron Therapeutics Predictive Daily Indicators
Aileron Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aileron Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Aileron Therapeutics Corporate Filings
F3 | 16th of April 2024 An amendment to the original Schedule 13D filing | ViewVerify |
10K | 15th of April 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
10th of April 2024 Other Reports | ViewVerify | |
F3 | 2nd of April 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
1st of April 2024 Other Reports | ViewVerify | |
8K | 29th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 15th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Aileron Therapeutics Forecast Models
Aileron Therapeutics' time-series forecasting models are one of many Aileron Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aileron Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Aileron Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Aileron Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aileron shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Aileron Therapeutics. By using and applying Aileron Stock analysis, traders can create a robust methodology for identifying Aileron entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.00 | 0.00 | |
Operating Profit Margin | 0.00 | 0.00 | |
Net Profit Margin | 0.00 | 0.00 | |
Gross Profit Margin | 0.00 | 0.00 |
Current Aileron Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aileron analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aileron analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
40.0 | Strong Buy | 1 | Odds |
Most Aileron analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aileron stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aileron Therapeutics, talking to its executives and customers, or listening to Aileron conference calls.
Aileron Stock Analysis Indicators
Aileron Therapeutics stock analysis indicators help investors evaluate how Aileron Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aileron Therapeutics shares will generate the highest return on investment. By understating and applying Aileron Therapeutics stock analysis, traders can identify Aileron Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 5.2 M | |
Common Stock Shares Outstanding | 4.6 M | |
Total Stockholder Equity | 6.9 M | |
Property Plant And Equipment Net | 19 K | |
Cash And Short Term Investments | 17.3 M | |
Cash | 17.3 M | |
Accounts Payable | 1.2 M | |
Net Debt | 74.1 M | |
50 Day M A | 5.3639 | |
Total Current Liabilities | 4.4 M | |
Other Operating Expenses | 15.3 M | |
Non Current Assets Total | 101 M | |
Non Currrent Assets Other | 2.2 M | |
Stock Based Compensation | 1.2 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Aileron Stock analysis
When running Aileron Therapeutics' price analysis, check to measure Aileron Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aileron Therapeutics is operating at the current time. Most of Aileron Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aileron Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aileron Therapeutics' price. Additionally, you may evaluate how the addition of Aileron Therapeutics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Aileron Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.42) | Return On Assets (0.15) | Return On Equity (0.27) |
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.